CALCIMAR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALCIMAR is an injectable small-molecule NDA approved in 1978 by Sanofi. The specific indication and mechanism of action are not currently documented in available data. This legacy product represents a mature therapeutic asset with long market presence.
LOE Approaching
As LOE approaches, the commercial team is likely consolidating operations with reduced headcount and focus shifting toward lifecycle extension or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the LOE-approaching lifecycle; roles on CALCIMAR typically involve managing decline, optimizing market access, and maximizing remaining revenue before generic erosion. Career development on this asset is limited; mobility to growth-stage products is strategically advisable.
Brand ManagerMedical Science Liaison
Worked on CALCIMAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.